Figure 2.

OSPREY Study Design. Schematic representation of dosing regimen. Three treatment periods included (1) loading doses (study drug was administered at baseline and at weeks 4 and 8, with an efficacy assessment at week 12); (2) matching q8 dosing cycles for brolucizumab and aflibercept, with a corresponding assessment period at week 40 (8 weeks after the last q8 dose administration for both treatments); and (3) a nonmatched period, during which all participants in the brolucizumab group received a q12 dose at week 44 and a second q12 cycle was completed at week 56, whereas participants in the aflibercept group continued on a q8 cycle with treatments at weeks 40 and 48. Sham injections were given to both treatment groups to preserve masking during the nonmatched period.